stoxline Quote Chart Rank Option Currency Glossary
  
Genelux Corporation (GNLX)
2.32  -0.13 (-5.31%)    07-18 15:53
Open: 2.5
High: 2.525
Volume: 102,267
  
Pre. Close: 2.45
Low: 2.27
Market Cap: 80(M)
Technical analysis
2024-07-18 3:20:34 PM
Short term     
Mid term     
Targets 6-month :  3.15 1-year :  3.68
Resists First :  2.7 Second :  3.15
Pivot price 2.21
Supports First :  2.08 Second :  1.71
MAs MA(5) :  2.46 MA(20) :  2.21
MA(100) :  4.01 MA(250) :  11.94
MACD MACD :  -0.1 Signal :  -0.2
%K %D K(14,3) :  75.4 D(3) :  82.3
RSI RSI(14): 46.6
52-week High :  30.44 Low :  1.71
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GNLX ] has closed below upper band by 42.9%. Bollinger Bands are 37.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.66 - 2.68 2.68 - 2.69
Low: 2.35 - 2.37 2.37 - 2.38
Close: 2.42 - 2.45 2.45 - 2.47
Company Description

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Headline News

Wed, 10 Jul 2024
Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires - Quantisnow

Fri, 07 Jun 2024
Genelux Corp director buys $32,812 in company stock - Investing.com

Wed, 05 Jun 2024
Genelux Corp. Bolsters Finance with Shares Sale and Strategy Plan - TipRanks

Fri, 24 May 2024
Why Genelux Corporation (GNLX) Shares Are Down 40% - MSN

Fri, 24 May 2024
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants - GlobeNewswire

Fri, 24 May 2024
Why Genelux Corporation (GNLX) Shares Are Down 40% - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 34 (M)
Held by Insiders 2.148e+007 (%)
Held by Institutions 17.5 (%)
Shares Short 2,440 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.537e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -101 %
Return on Assets (ttm) 437.5 %
Return on Equity (ttm) -82.2 %
Qtrly Rev. Growth 8000 %
Gross Profit (p.s.) 0.42
Sales Per Share 0.42
EBITDA (p.s.) -0.31
Qtrly Earnings Growth -1 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -20 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 5.35
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 1.69e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android